Dr. Reddy's Laboratories Ltd.

401 articles with Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

  9/3/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta® Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the U.S.

• Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

  8/27/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine® Capsules, 250 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India

  8/19/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of AVIGAN® 200 mg Tablets in India.

• Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market

  8/11/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® Otic Suspension, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Q1 FY21 Financial Results

  7/29/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended June 30, 2020.

• Dr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

  7/14/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. market.

• Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19

  7/1/2020

  Dr. Reddy's Laboratories Ltd. announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. and Global Response Aid for the development, manufacture and sales of Avigan® Tablets, a potential treatment of COVID-19.

• Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market

  6/19/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

  6/12/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt

  6/10/2020

  Dr. Reddy's Laboratories Ltd. announces that it has completed the acquisition of select divisions of Wockhardt Limited’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.

• Dr. Reddy’s Q4 & FY20 Financial Results

  5/20/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the fourth quarter and full year ended March 31, 2020 under International Financial Reporting Standards.

• Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020

  5/7/2020

  Dr. Reddy's Laboratories Ltd. will announce results for the fourth quarter and full year ended March 31, 2020 on Wednesday, May 20, 2020 after the Board Meeting.

• Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

  5/6/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP Injection, 4 mcg/mL, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market

  4/27/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® Tablets, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market

  4/14/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of authorized generic version of NitroDur® Transdermal Infusion System..

• Dr. Reddy's Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market

  4/14/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo® Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim® in the U.S. Market

  3/20/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim® Tablets, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces First-to-Market Launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market

  3/19/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan® Injection USP, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market

  3/17/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ziprasidone Mesylate for Injection, 20 mg /mL Single-dose Vials, the therapeutic generic equivalent of Geodon® Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market

  2/27/2020

  Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo® Delayed-Release Tablets approved by the U.S. Food and Drug Administration.